ArticlePloS one2018
Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism.PLoS pathogens · 2026Article
- FcγRI is the key determinant of antibody-mediated Zika virus infection of human placental macrophages.bioRxiv : the preprint server for biology · 2025Article
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- Influence of previous Zika virus infection on acute dengue episode.PLoS neglected tropical diseases · 2023Article
- Comparative Analysis of In Vitro Models to Study Antibody-Dependent Enhancement of Zika Virus Infection.Viruses · 2022Article
- Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model.Pathogens (Basel, Switzerland) · 2022Review
- Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective.Journal of the Indian Institute of Science · 2022Review
- Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques.PLoS neglected tropical diseases · 2021Article
- Evaluating the Safety of West Nile Virus Immunity During Congenital Zika Virus Infection in Mice.Frontiers in immunology · 2021Article
- The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease.Frontiers in immunology · 2021Article
- ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis.Cytokine · 2020Review
- Protective and enhancing interactions among dengue viruses 1-4 and Zika virus.Current opinion in virology · 2020Review
- The continued threat of emerging flaviviruses.Nature microbiology · 2020Review
- COVID-19: an Immunopathological View.mSphere · 2020Review
- Single cell immune profiling of dengue virus patients reveals intact immune responses to Zika virus with enrichment of innate immune signatures.PLoS neglected tropical diseases · 2020Article
- Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade.Frontiers in microbiology · 2020Review
- Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator.Viruses · 2019Article
- Cross-Protection of Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil.Emerging infectious diseases · 2019Article
- Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody dependent enhancement (ADE) has most often been associated with dengue virus (DENV). Studies using leukemia cell lines suggest that DENV specific antibodies can enhance Zika virus (ZIKV) infectivity, and vice versa. To examine the mechanisms of ADE of ZIKV infection in primary human cells, we assessed 40 serum samples obtained from convalescent DENV-1 or DENV-3 infected subjects. All sera tested exhibited high binding potency, while modest or none neutralization activities against ZIKV. Primary CD14+ monocytes, rather than B and T cells in peripheral blood mononuclear cells (PBMCs), were found to be the mediators of the enhancement of ZIKV infectivity by DENV immune sera. Monocyte-derived immature dendritic cells (DCs), but not mature DCs were highly permissive to ZIKV infection, whereas neither immature nor mature DCs could mediate enhanced ZIKV infection in the presence of DENV immune sera. In addition, antibody blocking of either FcγRI (CD64), or FcγRII (CD32), or FcγRIII (CD16) resulted in diminished ADE of ZIKV infection. Our findings provide an improved understanding of the pathogenesis of ZIKV infection, and inform rational vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.